Ovarian cancer remains a formidable challenge in oncology, often diagnosed at an advanced stage due to subtle symptomatology and limited early detection methods. The tumor microenvironment’s metabolic landscape is pivotal in sustaining cancer cell proliferation, survival, and metastasis. Here, FGFR1, a receptor tyrosine kinase, emerges as a potent suppressor whose signaling appears to reprogram metabolic pathways crucial for ovarian cancer cell growth. The research team, led by Jiang, Huang, and Dong, meticulously dissected how FGFR1 orchestrates this metabolic shift through the delicate regulation of SIRT3, a mitochondrial deacetylase previously implicated in cellular metabolism and oxidative stress response.

Central to the study is the identification of lactylation, a relatively new post-translational modification deriving from lactate, as a critical biochemical event modulated by FGFR1. Lactylation modifies lysine residues on histones and other proteins, thereby influencing gene expression and cellular functions. By leveraging cutting-edge proteomics and metabolomics analyses, the researchers demonstrated that FGFR1 signaling downregulates lactylation levels via SIRT3 activation. This modulation hampers the cancer cells’ ability to exploit glycolytic metabolism—a hallmark of many aggressive tumors—thereby impairing their proliferative capacity and malignancy.

This FGFR1-SIRT3-lactylation axis represents a hitherto unrecognized metabolic checkpoint in ovarian cancer. Importantly, the study elucidated that FGFR1 activation enhances SIRT3 deacetylase activity, which in turn reduces protein lactylation and shifts the metabolic balance away from aerobic glycolysis toward oxidative phosphorylation. This metabolic rewiring deprives cancer cells of the bioenergetic and biosynthetic resources essential for rapid growth and invasion. The findings compellingly position FGFR1 not just as a receptor involved in growth factor signaling but as a master regulator of cancer cell metabolism through epigenetic and enzymatic modifications.

Mechanistically, this work underscores the dual role of SIRT3 both as a mediator of mitochondrial function and as a modulator of histone lactylation status, thereby linking metabolic shifts to epigenetic regulation. The researchers used sophisticated in vitro and in vivo ovarian cancer models to validate their findings. Knockdown and overexpression experiments revealed that loss of FGFR1 signaling heightened lactylation, enhanced glycolytic flux, and promoted tumor growth, while reinstatement of FGFR1 curtailed these oncogenic processes. These functional studies highlight the therapeutic potential of restoring or mimicking FGFR1 activity to subvert ovarian cancer progression.

The implications of this discovery extend beyond ovarian cancer. Since metabolic reprogramming is a universal feature of many malignancies, targeting the FGFR1-SIRT3-lactylation pathway could have broad applications across diverse tumor types. Traditionally, FGFR1 has been studied for its proliferative and survival signaling roles in cancer; however, this study shifts the paradigm by demonstrating its tumor-suppressive function via metabolic modulation. This nuanced understanding challenges current approaches and encourages the design of novel therapeutic strategies that exploit metabolic vulnerabilities in cancer cells.

One of the exciting aspects of this research is its contribution to the burgeoning field of lactylation biology. Since lactylation was only recently characterized, its impact on cancer remained elusive. By linking lactylation dynamics to FGFR1 and SIRT3, the study provides concrete evidence that lactate-derived modifications are integral to controlling cancer metabolism and epigenetics. This insight could fuel further investigations into lactylation-targeted therapies, perhaps involving small molecules or peptides designed to modulate lactylation enzymes directly.

From a clinical perspective, the findings advocate for integrating FGFR1 status and metabolic profiling into ovarian cancer diagnostics and treatment planning. Biomarkers reflective of lactylation levels or SIRT3 activity might enable patient stratification and prognostication. Moreover, therapeutic agents that activate FGFR1 or enhance SIRT3 function could be developed and combined with existing chemotherapies to achieve synergistic antitumor effects. Given the notorious chemoresistance and relapse rates in ovarian cancer, metabolic intervention strategies could significantly improve patient outcomes.

Importantly, the study highlighted the robust interplay between metabolic enzymes and epigenetic modifications in cancer cells. By showing that metabolic enzymes like SIRT3 act beyond their canonical roles to influence histone modification landscapes, it bridges two major realms of cancer research—metabolism and epigenetics. This cross-disciplinary nexus is likely to spur more integrated studies aimed at unraveling how metabolic states remodel the chromatin environment to alter gene expression programs favoring tumor survival and dissemination.

The researchers utilized state-of-the-art CRISPR-Cas9 gene editing, stable isotope tracing, and high-resolution mass spectrometry to map the biochemical pathways involved. These technical advancements allowed for a comprehensive characterization of metabolic fluxes and post-translational modifications, lending robustness and precision to their conclusions. Their integrative approach sets a new standard for dissecting complex signaling-metabolic networks in cancer and exemplifies the power of multi-omic strategies.

Future research inspired by this study may focus on delineating how FGFR1 signaling is regulated in the tumor microenvironment and whether its metabolic regulatory functions are conserved in other cancer subtypes. Furthermore, exploring the crosstalk between lactylation and other epigenetic modifications could reveal hierarchical regulatory mechanisms that govern tumor metabolism and chromatin remodeling. Deciphering these layers of regulation will be crucial for identifying pivotal intervention points susceptible to pharmacologic manipulation.

This seminal work also raises important questions regarding the metabolic plasticity of cancer cells and their ability to adapt to therapeutic pressures. Since metabolic reprogramming is reversible and context-dependent, understanding how FGFR1 and SIRT3 influence this adaptability could inform strategies to prevent or overcome resistance phenomena. Targeting metabolic checkpoints such as lactylation represents an innovative route to undermine cancer cell survival strategies in a dynamic tumor ecosystem.

In summary, the study by Jiang, Huang, Dong, and colleagues represents a landmark contribution to cancer biology, elucidating a novel FGFR1-SIRT3-mediated mechanism that suppresses ovarian cancer progression by regulating lactylation and metabolic pathways. Their insights not only deepen our understanding of tumor metabolism but also open new therapeutic possibilities that could transform the management of ovarian cancer and potentially other malignancies. As research continues to unravel the complexity of cancer metabolism and epigenetics, the FGFR1-SIRT3-lactylation axis stands out as a promising molecular target demanding further exploration and clinical translation.

Subject of Research: Ovarian cancer progression and metabolic reprogramming mediated by FGFR1 and SIRT3-dependent lactylation

Article Title: FGFR1 suppresses ovarian cancer progression by modulating SIRT3-dependent lactylation and metabolic reprogramming

Article References:
Jiang, F., Huang, H., Dong, Z. et al. FGFR1 suppresses ovarian cancer progression by modulating SIRT3-dependent lactylation and metabolic reprogramming. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03054-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03054-6

The significance of the VEGF signaling pathway cannot be overstated; it orchestrates various biological processes that are critical for tumor development, including angiogenesis, which is the formation of new blood vessels. This process is vital for tumor survival and growth, as it provides the essential nutrients and oxygen that tumors need to thrive. In ovarian cancer, this pathway appears to be particularly active, contributing to the aggressive nature associated with the disease.

In their study, Zhao and team utilized advanced imaging techniques to visualize how ovarian cancer cells manipulate the VEGF pathway. The results revealed that the production of VEGF by tumor cells not only stimulates the growth of blood vessels but also promotes a hostile tumor microenvironment that fosters cancer progression. The researchers elucidated the complex signaling cascades that are triggered by VEGF, which ultimately lead to increased tumor cell proliferation and survival.

Moreover, the authors discussed how the dysregulation of the VEGF pathway presents opportunities for novel therapeutic strategies. By harnessing anti-VEGF therapies, clinicians may be able to inhibit angiogenesis in tumor settings. Such an approach could potentially slow down tumor growth and metastasis, providing a valuable addition to existing treatment regimens for ovarian cancer patients.

The study also explored the interactions between the immune system and the VEGF pathway. It is known that tumors often develop mechanisms to evade immune detection, and the VEGF signaling pathway plays a role in this process by promoting an immunosuppressive environment. Zhao and colleagues found that targeting this pathway may also enhance the efficacy of immunotherapy, allowing the immune system to recognize and attack cancer cells more effectively.

Leveraging animal models, the team conducted experiments that demonstrated how blocking VEGF signals led to a reduction in tumor size and spread. The findings support the notion that therapy aimed at inhibiting VEGF may be beneficial not only for treating existing tumors but also for preventing recurrence after surgery, a significant concern in ovarian cancer management.

This research is particularly timely, as ovarian cancer continues to pose serious treatment challenges due to its late diagnosis and the high rates of metastasis. The integration of VEGF-targeted therapies into treatment protocols could open new avenues for combatting this formidable cancer, giving hope to patients who currently face limited options.

Furthermore, the study highlights the importance of personalized medicine in cancer therapy. With the understanding that the VEGF pathway can vary among different ovarian cancer patients, there’s a strong case for biomarker-driven approaches to tailor treatments. By identifying which patients are more likely to benefit from anti-VEGF therapies, healthcare providers can make more informed decisions about treatment options, thereby optimizing outcomes.

The insights presented by Zhao et al. also underscore the need for further research into the molecular biology of ovarian cancer. Understanding the nuanced roles of various signaling pathways, including VEGF, will remain essential for developing innovative therapeutic approaches that are both effective and have manageable side effects.

The collaboration among researchers from various disciplines—oncology, molecular biology, and immunology—also exemplifies the multi-faceted approach needed in cancer research today. This study serves as a reminder that innovative therapies often emerge from interdisciplinary collaborations that capitalize on diverse expertise and methodologies.

In conclusion, the findings from Zhao and colleagues indeed hold promise for the future of ovarian cancer treatment. The focus on the VEGF pathway offers a compelling argument for the potential of anti-angiogenic therapies. By continuing to explore this pathway and its interactions with other cellular processes, researchers may unlock new strategies for combating not just ovarian cancer but many other malignancies as well.

As we look to the future, the integration of findings related to the VEGF pathway into clinical practice might very well shape the landscape of ovarian cancer treatment, promising a brighter outlook for patients grappling with this challenging disease.

Subject of Research: Vascular endothelial generating factor pathway in ovarian cancer

Article Title: Vascular endothelial generating factor pathway in ovarian cancer

Article References: Zhao, Y., Chen, Q., Li, J. et al. Vascular endothelial generating factor pathway in ovarian cancer. J Ovarian Res 18, 272 (2025). https://doi.org/10.1186/s13048-025-01864-3

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s13048-025-01864-3

Keywords: Ovarian cancer, VEGF pathway, angiogenesis, tumor microenvironment, immunotherapy, personalized medicine, molecular biology, anti-VEGF therapies.

Signaling networks in cancer cells act as vital communication channels, relaying information from the external environment to the nucleus where cellular decisions regarding growth, survival, or death are made. In ovarian cancer, several key signaling pathways, such as the PI3K/Akt and MAPK/ERK pathways, have been implicated in promoting cell survival and limiting the efficacy of chemotherapeutic agents. These pathways are often activated by various growth factors present in the tumor microenvironment, suggesting that ovarian cancer cells are not merely passive participants in their demise but rather active players in evasion strategies.

In conjunction with these signaling pathways, miRNAs have emerged as significant regulators of gene expression and cellular behavior in cancer. These small, non-coding RNA molecules can modulate the expression of genes involved in apoptosis, cell cycle regulation, and drug resistance. Dysregulation of miRNA expression profiles has been documented in ovarian cancer, illuminating their potential roles as both biomarkers and therapeutic targets. Understanding how specific miRNAs interact with key signaling pathways may shed light on the mechanisms driving chemoresistance.

One of the striking features of miRNAs is their ability to fine-tune gene expression post-transcriptionally, which allows for rapid cellular adaptation to stressors, including chemotherapeutic agents. For example, miR-21 has been shown to confer resistance to platinum-based therapies by inhibiting pro-apoptotic factors, while other miRNAs may promote apoptosis by targeting anti-apoptotic proteins. The balance of these opposing miRNA activities can significantly influence a tumor’s sensitivity to chemotherapy.

Recent studies have demonstrated that the crosstalk between miRNAs and signaling networks is critical for determining the fate of ovarian cancer cells in response to chemotherapy. This interplay may involve feedback loops where signaling molecules influence miRNA expression, which in turn modulates the activity of these same pathways, creating a complex web of interactions that ultimately dictate cell survival or death. Consequently, deciphering this network holds promise for identifying potential therapeutic interventions aimed at disrupting these pathways.

The tumor microenvironment further complicates the narrative of ovarian cancer chemoresistance. Factors such as a hypoxic environment, the presence of extracellular vesicles, and immune cell infiltration can create an optimal setting for cancer cells to thrive. These components can also influence miRNA expression and signaling pathway activation. For instance, hypoxia-inducible factors can upregulate certain miRNAs that confer resistance, suggesting a dynamic relationship between the tumor microenvironment and cellular signaling.

Furthermore, advancements in technologies such as high-throughput sequencing and bioinformatics have enabled researchers to map the intricate networks of miRNA and target gene interactions. This data reveals that multiple miRNAs can target a single gene, while a single miRNA may regulate multiple genes, illustrating the complexity of these regulatory networks. Such insights are invaluable for developing strategies to overcome chemoresistance, as they may inform the design of miRNA-based therapies or combination therapies that target these networks simultaneously.

In addition to miRNAs, long non-coding RNAs (lncRNAs) have also gained attention in the context of ovarian cancer. These RNA molecules, while not translated into proteins, play crucial regulatory roles in gene expression and have been implicated in various cancer-related processes, including chemoresistance. Some lncRNAs can modulate the expression of miRNAs and affect signaling pathways, further integrating them into the landscape of chemosensitivity.

The therapeutic implications of these findings are profound. By targeting specific signaling pathways or modulating miRNA expression, new therapeutic strategies could potentially restore chemosensitivity in resistant ovarian cancer cells. For example, combining traditional chemotherapy with inhibitors that target key signaling proteins, along with agents that modulate miRNA expression, could enhance treatment efficacy and prevent or overcome resistance.

In summary, the interrelationship between signaling networks and miRNA crosstalk represents a critical frontier in understanding ovarian cancer chemoresistance. As research continues to unveil the complexities of these interactions, it is hoped that actionable insights will emerge, fostering the development of innovative treatment strategies that could save lives. The quest for effective therapies in ovarian cancer is ongoing, but the recent focus on the molecular underpinnings of resistance offers a beacon of hope for patients facing this challenging diagnosis.

Continued collaboration between molecular biologists, oncologists, and therapeutic developers will be essential in translating these insights from basic research into clinical applications. As we deepen our understanding of how ovarian cancer cells evade treatment, the potential for significant advancements in patient care becomes increasingly tangible, heralding a new era in the fight against this formidable disease.

Subject of Research: The mechanisms of chemoresistance in ovarian cancer involving signaling networks and miRNA crosstalk.

Article Title: Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance.

Article References:

Nayak, R., Pandey, S., Kumar, D. et al. Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance.
J Ovarian Res 18, 185 (2025). https://doi.org/10.1186/s13048-025-01770-8

Image Credits: AI Generated

DOI: 10.1186/s13048-025-01770-8

Keywords: Ovarian cancer, chemoresistance, signaling networks, microRNA, therapeutic targets, tumor microenvironment, long non-coding RNAs, treatment strategies.

Long non-coding RNAs have emerged as crucial regulators in various physiological and pathological processes, including cancer. These RNA molecules do not code for proteins but are fundamental in controlling gene expression at the transcriptional and post-transcriptional levels. Evidence suggests that certain lncRNAs can promote metastasis by modulating cellular pathways involved in cell migration, invasion, and proliferation. This understanding highlights the potential for lncRNAs to serve as biomarkers that could predict the aggressiveness of ovarian cancer.

MicroRNAs, another class of non-coding RNAs, play an equally significant role in the regulation of gene expression. By binding to the 3′ untranslated regions of target mRNAs, miRNAs can effectively silence genes that would otherwise suppress cancer cell behavior. In ovarian cancer, a variety of miRNAs have been implicated in both tumor suppression and tumor promotion, often depending on the context and the specific targets they influence. This dual role complicates the landscape of ovarian cancer treatment but also opens avenues for novel therapeutic interventions that manipulate miRNA levels.

Circular RNAs are gaining attention for their unique structure and functional capabilities. Unlike traditional linear RNA molecules, circRNAs form a covalently closed loop, which renders them resistant to degradation. This stability allows circRNAs to serve as sponges for miRNAs, effectively sequestering them and preventing their interaction with target mRNAs. In ovarian cancer, certain circRNAs have been shown to facilitate tumor development and progression, suggesting their potential as biomarkers and therapeutic targets.

The interplay of these non-coding RNAs creates a complex landscape in ovarian cancer. For instance, lncRNAs might regulate the expression of specific miRNAs, leading to altered levels of gene expression that contribute to metastasis. Understanding these interactions is crucial for developing more targeted and effective therapies. As research progresses, the hope is that these molecular insights will lead to innovative treatments that can halt or even reverse the metastatic spread of ovarian cancer.

Furthermore, the functional diversity of non-coding RNAs raises important questions regarding their potential applications in clinical settings. For instance, can the expression profiles of lncRNAs, miRNAs, and circRNAs be leveraged to develop a reliable diagnostic tool that not only identifies ovarian cancer earlier but also stratifies patients according to their likely response to specific treatments? Current investigations are leaning towards creating a comprehensive molecular signature based on these non-coding RNAs, which could revolutionize how ovarian cancer is diagnosed and treated, paving the way for precision medicine tailored to individual patients.

Disease progression in ovarian cancer is often attributed to a variety of genetic and environmental factors that influence tumor biology. Nevertheless, the contribution of non-coding RNAs serves as a reminder that not all regulatory mechanisms are transcriptional. Understanding how these RNA molecules are expressed in various tumor microenvironments can provide insights into their roles during different stages of cancer development and metastasis.

Continued exploration of lncRNAs, miRNAs, and circRNAs may also reveal their involvement in patients’ responses to current therapies. Particularly, in ovarian cancer, where resistance to chemotherapy is a common and daunting challenge, deciphering the roles of non-coding RNAs could yield new strategies to overcome drug resistance. By employing RNA-targeted therapies, oncologists might be able to enhance the effectiveness of existing treatments and improve patient survival rates.

Alongside targeted RNA-based therapies, there is a growing interest in developing small molecule inhibitors that can disrupt the interactions between cancer-associated non-coding RNAs and their target mRNAs. As researchers decipher the specific roles of various lncRNAs, miRNAs, and circRNAs in ovarian cancer, the development of such inhibitors could represent a new frontier in therapeutic strategies. The integration of these approaches into clinical practice holds significant promise for enhancing treatment efficacy.

Collaboration between multidisciplinary teams—comprising oncologists, molecular biologists, and bioinformaticians—is essential to harness the full potential of non-coding RNAs for advancing ovarian cancer research. By sharing data and expertise, these collaborations can foster innovation, streamline the transition of laboratory findings into clinical applications, and ultimately accelerate the pursuit of effective, personalized treatments for ovarian cancer patients.

In conclusion, the exploration of long non-coding RNAs, microRNAs, and circular RNAs in ovarian cancer metastasis represents a frontier that is rich with possibilities. As the understanding of these non-coding RNAs continues to evolve, their potential as therapeutic targets and diagnostic tools becomes clearer, promising a new dawn in the fight against this formidable disease. The journey ahead is certainly challenging; however, the ultimate aim remains the same: to provide patients with the best possible outcomes through innovative and effective therapeutic strategies grounded in comprehensive molecular understanding.

As we stand at the intersection of discovery and application, it is essential to remain optimistic about the scientific advancements that have the potential to reshape the future of ovarian cancer treatment. Researchers and clinicians alike are called upon to continue their efforts toward uncovering the secrets held by non-coding RNAs and translating those discoveries into tangible benefits for patients battling ovarian cancer.

Subject of Research: The role of long non-coding RNAs, microRNAs, and circular RNAs in ovarian cancer metastasis and treatment approaches.

Article Title: Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches.

Article References:

Gosia, M., Doshi, G., Parab, S. et al. Long Non-Coding, Micro, and Circular RNAs in Ovarian Cancer Metastasis: Pathways and Treatment Approaches.
Reprod. Sci. (2025). https://doi.org/10.1007/s43032-025-01948-x

Image Credits: AI Generated

DOI:

Keywords: Ovarian cancer, long non-coding RNAs, microRNAs, circular RNAs, metastasis, biomarkers, treatment approaches, molecular biology, targeted therapy, gene expression.

Central to the study is the identification and expansion of TCF7-expressing T cells, which exhibit robust autologous tumor reactivity. Utilizing paired single-cell RNA sequencing (scRNA-seq) and T cell receptor sequencing (TCR-seq), the investigators meticulously characterized the heterogeneity within patient-derived TIL populations. This paired analytical approach allowed the researchers to identify distinct TCF7-positive subpopulations that preferentially expand during the TIL production process, illuminating potential therapeutic targets.

Among the T cell subpopulations, three stood out for their tumor reactivity and selection during ex vivo culture: CD8-positive TCF7-positive precursor exhausted T cells (Tpex), TCF7-positive GZMK-positive early effector memory T cells (Tem), and CD4-positive TCF7-positive T follicular helper (Tfh) cells. Notably, the CD8+ Tpex subset demonstrated self-renewal capabilities and the ability to differentiate into stem-like progeny, suggesting a pivotal role in sustaining long-term antitumor immunity once reinfused into the patient.

The implications of these findings are profound for immunotherapeutic strategies, as the persistence and functionality of infused TILs are critical determinants of durable clinical responses. The study further highlights CCR7 and CD200 as essential co-markers that identify tumor-reactive T cells possessing optimal therapeutic potential. Cells simultaneously expressing CCR7 and CD200 were found to enrich the TIL product with stem-like qualities, which could translate into enhanced persistence and tumor specificity in vivo.

By isolating and targeting the CCR7+CD200+ T cell subset, there is a tangible opportunity to refine and potentiate TIL therapy protocols. This selective enrichment strategy could overcome current limitations in TIL therapy persistence and specificity, addressing a pivotal hurdle in the treatment of ovarian cancer. Such advancements could elevate the efficacy of TIL therapies beyond melanoma, extending their benefits to ovarian cancer patients with historically poor prognoses.

This study’s methodology leveraged cutting-edge single-cell technologies, enabling a high-resolution dissection of the tumor microenvironment’s immune landscape. The pairing of scRNA-seq with TCR-seq provided a dual perspective: gene expression profiles alongside antigen receptor clonality and specificity. This holistic view was indispensable in discerning the nuanced differentiation states and functional hierarchies within TIL populations.

Moreover, the identification of TCF7 as a biomarker of stem-like qualities within TILs aligns with emerging paradigms in T cell biology. TCF7, a transcription factor associated with memory T cell differentiation, plays a pivotal role in maintaining T cell self-renewal and multipotency. Its expression within tumor-reactive lymphocytes underscores the importance of preserving these stem-like characteristics to sustain antitumor immune responses long-term.

The expansion of these TCF7-expressing subpopulations during TIL production also raises intriguing questions about the ex vivo culture conditions. Understanding the molecular and environmental cues that drive selective proliferation could inform protocol optimizations that maximize the yield of therapeutically valuable T cell subsets. This precision cultivation approach promises to augment the functional potency of the final TIL infusion product.

Overall, this research marks a significant leap forward in the conceptual and practical framework of TIL therapy for ovarian cancer. It offers a clear roadmap for the development of next-generation adoptive cell therapies that incorporate phenotypic and functional selection criteria. Such rational design is essential to translate preclinical discoveries into tangible patient benefits, particularly in a cancer type where immune-based therapies have lagged behind other malignancies.

The translational potential of discerning CCR7+CD200+ tumor-reactive T cells cannot be overstated. By enriching for these populations, future clinical protocols might not only improve response rates but also achieve more sustained remissions, minimizing relapse risk. These findings align with the broader immunotherapy goal of producing memory-like T cells that exhibit resiliency and adaptability within the immunosuppressive tumor microenvironment.

As ovarian cancer remains a leading cause of gynecological cancer mortality, innovative approaches such as these offer hope for improving clinical outcomes. The detailed characterization and selective expansion of tumor-specific TILs provide a beacon for personalized medicine strategies, tailoring treatments to the unique immune landscape of each patient’s tumor.

In summary, this study encapsulates the intersection of advanced single-cell profiling, immunology, and cellular therapy innovation. It underscores the essentials of TIL heterogeneity, stem-like T cell biology, and phenotypic marker-based selection in refining adoptive cell therapies. These insights not only enrich our understanding of ovarian cancer immunobiology but also chart a course for more effective and durable immunotherapies that could redefine the standard of care.

Subject of Research: Tumor-Infiltrating Lymphocyte Therapy for Ovarian Cancer

Article Title: Identification and Expansion of Tumor-Reactive TCF7+ T Cell Subpopulations in Ovarian Cancer for Enhanced TIL Therapy

Web References: 10.1007/s11427-025-2958-3

Keywords: Tumor-infiltrating lymphocytes, TIL therapy, ovarian cancer, TCF7, CCR7, CD200, single-cell RNA sequencing, TCR sequencing, precursor exhausted T cells, immunotherapy, stem-like T cells, adoptive cell therapy